US · XAIR
Beyond Air, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Garden City, NY 11530
- Website
- beyondair.net
Price · as of 2025-03-31
$0.51
Market cap 4.87M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $59.45 | +11,466.15% |
| Intrinsic Value(DCF) | $1.52 | +195.72% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $101.72 | ||||
| 2020 | $135.80 | $27,902.64 | $0.00 | $0.00 | $2,437.03 |
| 2021 | $110.20 | $52.16 | $6.42 | $0.00 | $697.54 |
| 2022 | $106.20 | $50.71 | |||
| 2023 | $117.90 | ||||
| 2024 | $23.40 | $0.00 | $0.00 | ||
| 2025 | $3.80 | $59.45 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Beyond Air, Inc.'s (XAIR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $59.45
- Current price
- $0.51
- AI upside
- +11,466.15%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.52
+195.72% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XAIR | Beyond Air, Inc. | $0.51 | 4.87M | +11,466% | +196% | — | — | -0.27 | 0.95 | 3.47 | -0.42 | — | 1.04 | -44.89% | -1202.08% | -1258.43% | -250.98% | -332.73% | -111.42% | 0.86 | -14.75 | 3.20 | 1.56 | -0.17 | -6210.00% | 21967.00% | -2859.00% | -342.82% | -7.64 | -329.47% | 0.00% | 0.00% | 0.00% | -0.40 | -0.40 | 4.76 | -17.17 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.52 | 8.68M | +449% | -22% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| CLRB | Cellectar Biosciences, In… | $3.25 | 10.36M | — | — | — | — | -0.26 | 0.82 | — | 0.22 | — | 0.82 | 0.00% | — | — | -17221.69% | 330.97% | -237.45% | 0.03 | — | 2.58 | 2.48 | 0.44 | -6010.00% | — | 4346.00% | -406.92% | -5.07 | 304.82% | 0.00% | 0.00% | 117.61% | 0.21 | 0.23 | — | -18.97 |
| CODX | Co-Diagnostics, Inc. | $2.30 | 2.57M | +1,244% | +270% | — | +1,660% | -13.54 | 9.38 | 130.17 | -12.45 | -406.20 | 18.07 | 74.48% | -1023.75% | -961.37% | -53.65% | -140.21% | -47.25% | 0.04 | — | 4.41 | 4.08 | 0.02 | 333.00% | -4253.00% | 2754.00% | -5.87% | -3.99 | -104.61% | 0.00% | 0.00% | 0.00% | -12.03 | -16.12 | 123.12 | 29.30 |
| IINN | Inspira Technologies Oxy … | $0.58 | 13.97M | — | — | — | — | -1.42 | 3.64 | — | -1121.82 | — | 3.64 | 0.00% | — | — | -219.74% | 7.39% | -127.19% | 0.58 | — | 2.02 | 1.71 | 234.68 | -9994.00% | — | -426.00% | -60.68% | -2.78 | -6254.43% | 0.00% | 0.00% | 0.00% | 1104.79 | -1.31 | — | -8.52 |
| LFWD | Lifeward Ltd. | $7.40 | 11.28M | +6% | +25,985% | — | — | -0.49 | 0.75 | 0.55 | -0.32 | -1.71 | 1.25 | 32.01% | -76.19% | -112.78% | -88.56% | -118.09% | -61.79% | 0.05 | -152.76 | 2.08 | 1.27 | 0.24 | 2857.00% | 8524.00% | 468.00% | -153.36% | -2.12 | -131.16% | 0.00% | 0.00% | 0.00% | -0.41 | -0.37 | 0.32 | -12.27 |
| LYRA | Lyra Therapeutics, Inc. | $1.01 | 1.79M | +2,414% | +280% | — | — | -6.69 | 53.92 | 407.49 | -10.27 | -49.59 | 53.92 | 100.00% | -6280.83% | -6090.94% | -184.99% | -1017.13% | -89.43% | 2.97 | — | 3.41 | 3.21 | 0.10 | 1349.00% | -154.00% | 1243.00% | -11.57% | -5.54 | -763.78% | 0.00% | 0.00% | 1.72% | -6.42 | -8.55 | 403.45 | -5.91 |
| SINT | Sintx Technologies, Inc. | $2.89 | 7.97M | +19,466% | -54% | — | +21,505% | -0.22 | 0.63 | 1.98 | -0.30 | — | 0.64 | 34.91% | -1127.37% | -884.75% | -174.07% | -193.62% | -88.98% | 1.03 | -484.38 | 2.41 | 1.91 | -0.04 | -2178.00% | -5257.00% | -3628.00% | -378.55% | -4.36 | -128.63% | 0.00% | 0.00% | 40.16% | -0.21 | -0.31 | 2.32 | -46.07 |
| TNON | Tenon Medical, Inc. | $0.87 | 7.5M | +21,018% | +210,838% | — | — | -0.12 | 0.26 | 0.48 | 0.35 | — | 0.26 | 52.21% | -420.08% | -417.24% | -405.19% | -38777.46% | -168.93% | 0.07 | -404.88 | 4.39 | 3.96 | 0.47 | -8360.00% | 1192.00% | -1977.00% | -637.69% | -5.29 | -28349.30% | 0.00% | 0.00% | 350.78% | 0.33 | 0.45 | -1.38 | -13.04 |
| TRIB | Trinity Biotech plc | $0.72 | 7.47M | +6,885% | -61% | — | — | -0.39 | -0.35 | 0.20 | -6.39 | — | -0.14 | 34.83% | -34.38% | -51.64% | 107.52% | -42.24% | -39.07% | -2.86 | -2.21 | 1.28 | 0.62 | -5.65 | -4469.00% | 831.00% | 1533.00% | -115.03% | -0.13 | -28.45% | 0.00% | 0.00% | 0.00% | -5.10 | -7.58 | 1.75 | -0.99 |
About Beyond Air, Inc.
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
- CEO
- Steven Adam Lisi
- Employees
- 107
- Beta
- 0.39
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.52 ÷ $0.51) − 1 = +195.72% (DCF, example).